Keros Therapeutics, Inc. (KROS) shares ended the last trading session 9.8% higher at $15.19. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the ...

Additionally, Keros Therapeutics reported positive clinical data for its DMD drug candidate, KER-065, from a Phase 1 trial presented at a recent conference. The U.S. Food and Drug Administration has ...

Additionally, Keros reported positive data from its Phase 1 trial of KER-065, a treatment candidate for Duchenne muscular dystrophy (DMD), at a recent medical conference. In a regulatory development, ...

Keros, a clinical-stage biopharmaceutical company focused on developing therapeutics for disorders linked to transforming growth factor-beta protein signaling, stated it continues to target a first ...

Agrees to Repurchase of All Shares Held By ADAR1 Capital Management and Pontifax Venture Capital Plans to Commence Tender Offer to Repurchase up to $194 Million of Additional Shares LEXINGTON, Mass., ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Keros Therapeutics ( (KROS)) has provided ...

LEXINGTON, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel ...

Keros Therapeutics has shaken up its leadership structure as the biotech attempts to shake off the failure of its blood pressure drug by going all in on an early-stage Duchenne muscular dystrophy (DMD ...

Fintel reports that on June 10, 2025, B of A Securities downgraded their outlook for Keros Therapeutics (NasdaqGM:KROS) from Buy to Neutral. Analyst Price Forecast Suggests 89.41% Upside As of June 2, ...

Bank of America Securities analyst Jason Zemansky downgraded Keros Therapeutics, Inc. (NASDAQ:KROS) from Buy to Neutral, lowering the price forecast from $32 to $18. Zemansky noted that Keros has ...